New screening aims to match cancer patients with personalized T-Cell treatments
NCT ID NCT05812027
First seen Nov 17, 2025 · Last updated Jun 20, 2026 · Updated 23 times
Summary
This study screens up to 1,150 adults with advanced solid tumors (like head and neck, cervical, or lung cancer) to see if they have the right genetic markers and tumor features for future T-cell therapies. Researchers will test blood and tumor samples for HLA type and other markers. The goal is to find eligible participants for TScan Therapeutics' upcoming treatment trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Allegheny Hospitals Network
Pittsburgh, Pennsylvania, 15224, United States
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Columbia University Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
-
HonorHealth Research and Innovation Institute
Scottsdale, Arizona, 85258, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Memorial Healthcare System
Hollywood, Florida, 33021, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40202, United States
-
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
Oncology Hematology Care
Cincinnati, Ohio, 45242, United States
-
Orlando Health
Orlando, Florida, 32806, United States
-
Providence Cancer Institute Franz Clinic
Portland, Oregon, 97213, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
The Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
University of California San Diego
San Diego, California, 92037, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Miami, Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
University of Minnesota, Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of South Florida
Tampa, Florida, 33606, United States
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this screening could help identify patients who may benefit from future T-cell therapies for advanced solid tumors.
What could go wrong
This is only a screening study, not a treatment trial. It does not test any therapy, so there is no direct benefit to participants.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.